DETERMINATION OF TRACERS WITHIN SUBJECTS

• US 20100272652A1
• Filed: 03/26/2010
• Published: 10/28/2010
• Est. Priority Date: 03/26/2009
• Status: Abandoned Application

• Current Assignee: Seventh Sense Biosystems, Inc.
• Original Assignee: Seventh Sense Biosystems, Inc.
• Inventors: Levinson, Douglas A.
• Application Number:
  US12/748,316
• Publication Number:
  US 20100272652A1
• Time in Patent Office: Days
• US Class Current: 424/9.800
• CPC Class Codes: A61K 47/549 Sugars, nucleosides, nucleotides or nucleic acids
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61K 47/62 the modifying agent being a protein, peptide or polyamino acid
• CPC Class Codes: A61K 49/0006 Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
• CPC Class Codes: A61K 49/006 Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention generally relates to the use of tracers, for example, to track a substance that has been administered to a subject. A tracer may be separate from the substance to be administered, or in some cases, the tracer and the substance are chemically bonded to each other. When administered to a subject (e.g., ingested), the tracer and the substance to be administered may be absorbed and/or metabolized by the subject, and the pharmacokinetic activity of the tracer within the subject may be related to the pharmacokinetic activity of the substance. Thus, by following the pharmacokinetic activity of the tracer, the pharmacokinetic activity of the substance may be determined. The tracer itself may be determined within a subject using any suitable method, depending on the tracer. As an example, the tracer may be determined by administering an indicator able to interact with the tracer. For instance, the indicator may be applied to the skin of the subject, and the indicator may give a different visual appearance based on the concentration of the tracer, or otherwise exhibit a determinable change in a property of the indicator. Other aspects of the invention are generally directed to methods of making or using tracers, methods of promoting the making or use of such tracers, kits involving such tracers, and the like.

Claims

1. A method, comprising:

providing a substance, the presence and/or amount of which is to be determined in association with a subject;

offering, to the subject, a composition comprising the substance and a tracer able to be introduced into and be determined in association with the subject; and

determining whether the substance was administered to the subject by determining the tracer in association with the subject.

2. The method of claim 1, wherein the substance and the tracer are present in a composition offered to the subject.

3. The method of claim 1, wherein the substance is a drug.

6. The method of claim 1, wherein the composition is a liquid containing the tracer and the substance.

7. The method of claim 1, wherein the composition is a solid.

10. The method of claim 1, wherein the tracer and the substance are chemically unbonded to each other.

11. The method of claim 1, wherein the tracer and the substance are chemically bonded to each other.

13. The method of claim 1, comprising wherein the pharmacokinetic absorption profile of the tracer and the substance are substantially similar.

14. The method of claim 1, wherein the composition is administered orally to the subject.

15. The method of claim 1, wherein the composition is administered parenterally to the subject.

18. The method of claim 1, wherein the indicator comprises particles.

39. The method of claim 1, wherein the tracer comprises a protein.

40. The method of claim 1, wherein the tracer comprises inulin.

41. The method of claim 1, wherein the tracer has a molecular weight of less than about 1000 Da.

42. The method of claim 1, wherein the tracer comprises creatinine.

45. The method of claim 1, wherein determining the tracer in association with the subject comprises quantitatively determining the tracer.

4-5. -5. (canceled)

8-9. -9. (canceled)

12. (canceled)

16-17. -17. (canceled)

19-38. -38. (canceled)

43-44. -44. (canceled)

46. A method, comprising:

administering a composition comprising a tracer and a substance to a subject; and

determining activity of the substance within the subject by determining the tracer within the subject.

47. The method of claim 46, wherein the substance is a drug.

49. The method of claim 46, wherein the tracer and the substance are chemically unbonded to each other.

53. The method of claim 46, wherein the composition is administered orally to the subject.

62. The method of claim 46, comprising determining the pharmokinetic absorption profile of the drug within the subject.

48. (canceled)

50-52. -52. (canceled)

54-56. -56. (canceled)

58-61. -61. (canceled)

63. A method, comprising;

administering a composition comprising a tracer and a pharmaceutically acceptable carrier to a subject; and

administering an indicator responsive to the tracer to the skin of the subject.

65. The method of claim 63, wherein the indicator comprises particles.

69. The method of claim 63, wherein the composition is administered orally to the subject.

70. The method of claim 63, wherein the composition is administered parenterally to the subject.

71. The method of claim 63, wherein the drug and the tracer exhibit substantially the same pharmacokinetic absorption.

72. The method of claim 63, further comprising determining the indicator after administering the indicator.

64. (canceled)

66-68. -68. (canceled)

73. (canceled)

74. A method, comprising:

administering, to a subject, a composition comprising a tracer and a substance able to be introduced and be determined in the subject; and

administering an indicator responsive to the tracer to the skin of the subject, the indicator able to change a property upon response to the tracer.

75. The method of claim 74, wherein the property is a visual property.

77. The method of claim 74, wherein the indicator comprises particles.

78. The method of claim 77, wherein the property is aggregation of particles.

80. The method of claim 74, wherein the composition further comprises a drug.

76. (canceled)

79. (canceled)

81-87. -87. (canceled)

88. A method, comprising:

offering, to a subject, an ingestible composition comprising a tracer and an ingestible substance, and a dermally-applicable composition comprising an indicator able to change a visual property upon exposure to the tracer.

90. The method of claim 88, wherein the substance is a drug.

98. The method of claim 88, wherein the indicator comprises particles.

89. (canceled)

91-97. -97. (canceled)

99. (canceled)

100. A method, comprising:

determining a substance within a subject by monitoring a tracer within the subject.

101. The method of claim 100, wherein the tracer and the substance are chemically unbonded to each other.

104. The method of claim 100, further comprising simultaneously administering the tracer and the active ingredient to the subject.

105. The method of claim 100, wherein the substance is a drug.

107. The method of claim 100, wherein an indicator is used to monitor the tracer.

102-103. -103. (canceled)

106. (canceled)

108-111. -111. (canceled)

112. A method, comprising:

determining an exogenous tracer within a subject indicative of a substance administered to the subject.

113. The method of claim 112, wherein the active substance and the exogenous tracer are simultaneously administered to the subject.

114. The method of claim 112, wherein the active substance and the exogenous tracer are each contained within a composition administered to the subject.

115. The method of claim 112, wherein the substance is a drug.

125. The method of claim 112, wherein the composition is administered orally to the subject.

126. The method of claim 112, wherein the composition is administered parenterally to the subject.

116-122. -122. (canceled)

124. (canceled)

127. A kit, comprising;

a composition comprising a tracer and a carrier containing the tracer; and

a skin delivery device comprising an indicator responsive to the tracer.

129. The kit of claim 127, wherein the indicator comprises particles.

131. The kit of claim 127, wherein the skin delivery device is a skin patch.

132. The kit of claim 127, further comprising instructions for use of the composition and/or the skin delivery device.

128. (canceled)

130. (canceled)

133. A kit, comprising;

a composition comprising a tracer and a substance; and

a skin delivery device comprising an indicator responsive to the tracer.

134. The kit of claim 133, further comprising a carrier containing the tracer.

135. The kit of claim 134, wherein the carrier comprises the substance.

136. The kit of claim 133, wherein the substance is a drug.

137-140. -140. (canceled)

141. A kit, comprising:

a tracer;

a substance; and

instructions for administering the tracer and the substance to a subject, and determining the tracer within the subject.

142. The kit of claim 141, wherein the substance is a drug.

144. The kit of claim 141, wherein the indicator comprises particles.

143. (canceled)

145-146. -146. (canceled)

148. A method, comprising:

offering, to a subject, an ingestible composition comprising a tracer and an ingestible substance, and a device comprising an indicator able to change a visual property upon exposure to the tracer.

149. The method of claim 148, wherein the substance is a drug.

151. The method of claim 148, wherein the composition is a liquid containing the tracer and the substance.

152. The method of claim 148, wherein the composition is a solid.

153. The method of claim 148, wherein the tracer and the substance are chemically unbonded to each other.

154. The method of claim 148, wherein the tracer and the substance are chemically bonded to each other.

157. The method of claim 148, wherein the indicator comprises particles.

150. (canceled)

155-156. -156. (canceled)

158. (canceled)